A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis-Reference-Cited by-同舟云学术

A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Published:2012-03-06 Issue:6 Volume:157 Page:766-769
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mollee Peter,Tiley Campbell¹,Cunningham Ilona²,Moore John³,Prince H. Miles⁴,Cannell Paul⁵,Gibbons Steve⁶,Tate Jill⁷,Paul Sanjoy⁸,Mar Fan Helen,Gill Devinder S.⁹

Affiliation:

1. Haematology Department; Gosford Hospital; Gosford; Australia

2. Concord Repatriation General Hospital; Sydney; Australia

3. St Vincent's Hospital; Sydney; Australia

4. Divison of Haematology; Peter MacCallum Cancer Centre; Melbourne; Australia

5. Hematology Department; Royal Perth Hospital; Perth; Australia

6. Christchurch Hospital; Christchurch; New Zealand

7. Department of Chemical Pathology; Pathology Queensland; Brisbane; Australia

8. Queensland Clinical Trials & Biostatistics Centre; School of Population Health; University of Queensland; Brisbane; Australia

9. Haematology Department; Pathology Queensland; Princess Alexandra Hospital; Brisbane; Australia

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09080.x/fullpdf

Reference10 articles.

1. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma;Bosanquet;Cancer Chemotherapy and Pharmacology,1984

2. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement;Dietrich;Blood,2010

3. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation;Dispenzieri;Blood,2004a

4. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis;Dispenzieri;Journal of Clinical Oncology,2004b

5. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis;Gertz;Leukaemia & Lymphoma,2008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis;Internal Medicine Journal;2022-10

2. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study;Amyloid;2019-04-03

3. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group;Internal Medicine Journal;2015-04

4. Emerging treatments for amyloidosis;Kidney International;2015-03

5. Guidelines on the management of AL amyloidosis;British Journal of Haematology;2014-10-10